The cost of mapping trachoma: data from the Global Trachoma Mapping Project by Trotignon, G et al.
RESEARCH ARTICLE
The cost of mapping trachoma: Data from the
Global Trachoma Mapping Project
Guillaume Trotignon1☯*, Ellen Jones2☯, Thomas Engels1☯, Elena Schmidt1‡, Deborah
A. McFarland3‡, Colin K. Macleod4‡, Khaled Amer5, Amadou A. Bio6, Ana Bakhtiari7,
Sarah Bovill2, Amy H. Doherty8, Asad Aslam Khan9, Mariamo Mbofana10,
Siobhain McCullagh2, Tom Millar2, Consity Mwale11, Lisa A. Rotondo8, Angela Weaver12,
Rebecca Willis7, Anthony W. Solomon4,13‡
1 Research Department, Sightsavers, Haywards Heath, United Kingdom, 2 Neglected Tropical Diseases
Department, Sightsavers, Haywards Heath, United Kingdom, 3 Rollins School of Public Health, Emory
University, Atlanta, GA, United States of America, 4 Clinical Research Department, London School of
Hygiene & Tropical Medicine, London, United Kingdom, 5 Prevention of Blindness Programme, Ministry of
Health, Cairo, Egypt, 6 Programme National de Lutte Contre les Maladies Transmissibles, Ministère de la
Sante´, Cotonou, Benin, 7 Task Force for Global Health, Atlanta, GA, United States of America, 8 RTI
International, Washington, D.C., United States of America, 9 King Edward Medical University, Lahore,
Pakistan, 10 Health Programa Nacional de Oftalmologia, Ministerio da Saude, Maputo, Moc¸ambique,
11 Provincial Health Office, Ndola, Zambia, 12 United States Agency for International Development,
Washington, D.C., United States of America, 13 Department of Control of Neglected Tropical Diseases,
World Health Organization, Geneva, Switzerland
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* gtrotignon@sightsavers.org
Abstract
Background
The Global Trachoma Mapping Project (GTMP) was implemented with the aim of complet-
ing the baseline map of trachoma globally. Over 2.6 million people were examined in 1,546
districts across 29 countries between December 2012 and January 2016. The aim of the
analysis was to estimate the unit cost and to identify the key cost drivers of trachoma preva-
lence surveys conducted as part of GTMP.
Methodology and principal findings
In-country and global support costs were obtained using GTMP financial records. In-country
expenditure was analysed for 1,164 districts across 17 countries. The mean survey cost
was $13,113 per district [median: $11,675; IQR = $8,365-$14,618], $17,566 per evaluation
unit [median: $15,839; IQR = $10,773-$19,915], $692 per cluster [median: $625; IQR =
$452-$847] and $6.0 per person screened [median: $4.9; IQR = $3.7-$7.9]. Survey unit
costs varied substantially across settings, and were driven by parameters such as geo-
graphic location, demographic characteristics, seasonal effects, and local operational con-
straints. Analysis by activities showed that fieldwork constituted the largest share of in-
country survey costs (74%), followed by training of survey teams (11%). The main drivers of
in-country survey costs were personnel (49%) and transportation (44%). Global support
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Conclusion
This study provides the most extensive analysis of the cost of conducting trachoma preva-
lence surveys to date. The findings can aid planning and budgeting for future trachoma sur-
veys required to measure the impact of trachoma elimination activities. Furthermore, the
results of this study can also be used as a cost basis for other disease mapping pro-
grammes, where disease or context-specific survey cost data are not available.
Author summary
There are currently few data sets available to aid programmes in planning and budgeting
for population-based surveys in low- and middle- income countries. With the objective of
identifying cost drivers and key variables influencing prevalence survey costs, the authors
collected expenses incurred during the Global Trachoma Mapping Project (GTMP)
which surveyed 2.6 million people across 29 countries. Expenditure from surveying 1,164
districts in 17 countries was analysed. Our results showed that the majority of in-country
expenditure was spent on personnel (per diems, accommodation, meals and beverages)
(49%) and local transportation (44%) and that the median survey expenditure was US
$11,675 per district (or US$15,839 per evaluation unit, US$625 per cluster and US$4.9 per
person examined). There were large variations in survey unit costs across settings, based
on local geographic, demographic, seasonal effects and local operational characteristics. In
addition, the resources required for the global support and coordination of the GTMP
were analysed and amounted to US$5.1m (US$3,318 per district or US$5,668 per EU).
Global support expenses can be substantial for a large multi-country mapping exercise
conducted in a limited period of time such as the GTMP. Findings from this study can be
used to inform other disease mapping projects, and to inform planning and budgeting for
the prevalence surveys that will assess the impact of trachoma elimination interventions.
Introduction
An estimated 285 million people worldwide live with visual impairment, including 39 million
who are blind [1]. Trachoma is the leading infectious cause of avoidable blindness, responsible
for the visual impairment of about 1.9 million people, of whom 0.5 million are irreversibly
blind [2]. The disease is a public health problem in 42 countries, with just over 200 million
people being at risk, the majority of whom are in Sub-Saharan Africa [3].
The World Health Organization (WHO) has called for global elimination of trachoma as a
public health problem by 2020. To achieve it, WHO recommends the use of a strategy known
as SAFE. This includes (i) Surgery to correct the advanced stage of the disease, known as tra-
chomatous trichiasis (TT), when one or more eyelashes rub on the eyeball; (ii) Antibiotics to
clear ocular Chlamydia trachomatis infection, and (iii) Facial cleanliness and (iv) Environmen-
tal improvement to reduce infection transmission. The “S” component targets individuals,
while “A”, “F” and “E” are community-based interventions. WHO recommends that “A”, “F”
and “E” are delivered for at least three years in districts in which10% of children aged 1–9
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years are estimated to have the sign trachomatous inflammation-follicular (TF), increasing to
5 years in districts in which30% of children have TF. Data on the prevalence of TF and TT
at district level (where “districts” generally contain populations of 100,000–250,000 people) are
therefore vital for planning interventions and judging the subsequent success of those efforts
[4].
The Global Trachoma Mapping Project (GTMP) was launched in 2012, with the aim of
completing the baseline map of trachoma worldwide by estimating the prevalence of TF and
TT in all suspected trachoma-endemic areas for which prevalence data were unavailable.
Between December 2012 and January 2016 the GTMP examined more than 2.6 million people
across 29 countries (Fig 1).
In addition to providing the evidence base for commencing district-wide implementation
of the SAFE strategy, prevalence surveys are also used to evaluate the impact of trachoma elim-
ination interventions. The need for such surveys will increase in the near future, as elimination
efforts are ramped up globally. The cost of population-based surveys has been cited as a reason
for delays in conducting impact and surveillance surveys, so providing data on actual costs is
important to inform debate [5]. The existing literature on the economics of trachoma elimina-
tion is sparse, with only one published study addressing the incremental costs of prevalence
surveys [5], and several other papers focusing on socioeconomic burden, and the cost-effec-
tiveness of interventions [6–9].
Methods
Surveys were implemented by health ministries, supported by local nongovernmental organi-
sation (NGO) partners. All surveys followed a standardised methodology, as described in detail
elsewhere [4].
Fig 1. Countries Surveyed as Part of the Global Trachoma Mapping Project. Fig 1 was adapted from an open source map retrieved on Natural Earth
Data at http://www.naturalearthdata.com/about/terms-of-use.
https://doi.org/10.1371/journal.pntd.0006023.g001
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Survey design
Surveys were carried out in areas defined as evaluation units (EUs). Evaluation units were used
to address two issues: (1) local definitions of a “district” vary greatly in terms of population
size and geographical area, and (2) WHO encourages baseline trachoma prevalence surveys to
be conducted at larger-than-district level, where trachoma is expected to be highly and widely
endemic [10]. EUs (rather than districts) have been used as the principal unit of analysis in
order to allow comparability of data on survey costs in this paper. However, cost per districts
and clusters are also reported in the tables.
Each EU-level survey followed a multi-stage cluster random sampling methodology. First-
level clusters were broadly synonymous with “villages”, or represented the lowest administra-
tive unit covered by census data. In each first-level cluster, teams randomly selected a number
of households for inclusion, corresponding to the number of households that a team could
screen in one day. To estimate a 10% prevalence of TF with absolute precision of ±3% at the
95% confidence level, 1,019 children aged 1–9 years needed to be sampled, including a design
effect of 2.65 to account for the clustered design; this was inflated by a factor of 1.2 to allow for
non-response. The number of first-level clusters required varied based on the local demo-
graphical situation, with 20 set as a minimum.
Field teams comprised one trachoma grader and one data recorder, and in most cases a
driver and a local guide. (In a small number of subprojects, due to local norms, one male grader
plus one female grader were needed per team to grade male and female subjects, respectively.)
Graders and recorders were recruited by the local health ministry and trained by GTMP-certi-
fied trainers, using a standardised training protocol and materials, over five days, consisting of
intensive classroom sessions, field based training and testing [4]. In the field, the teams were
supervised by an ophthalmologist or senior ophthalmic nurse, who was appointed for every
seven to ten teams on average. In selected households, all residents over the age of one year
were invited to participate. Consenting individuals were examined for the signs of TT, TF and
trachomatous inflammation-intense (TI). Additional questions were asked about households’
access to water and sanitation (WASH), and observation was undertaken of latrine facilities, if
present. In some surveys, data were also collected on other diseases of local importance.
All data were captured electronically, using a purpose-built Open Data Kit-based Android
smartphone application, and uploaded to a cloud-based server for quality assurance checks
(including Global Positioning System (GPS) localisation of households surveyed) and subse-
quent data cleaning and analysis.
Costing approach and inclusion criteria
The GTMP was implemented as a series of subprojects. A subproject was a group of surveys
conducted in a defined geographical area, for which a unique budget was established and expen-
diture reports prepared. To ensure comparability across countries and surveys, a number of
inclusion criteria were introduced for this study. Mapping subprojects were only included in
the costing analysis if they 1) followed the standardised GTMP methodologies; 2) only collected
data on trachoma and WASH, or were integrated surveys of trachoma and other diseases in
which the trachoma- and WASH-data-related expenditure could be explicitly identified.
In this study, the cost of conducting baseline trachoma surveys included only financial
expenditure covered by the GTMP. An activity-based costing accounting model was used to
analyse survey expenditure. Data on in-kind contributions and expenditure from project part-
ners or health ministries that would have been incurred in the absence of the mapping project
were not collected, with the exception of vehicles. For example, any per diems received by
health ministry staff during field work were included, but their base salaries were not. When
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vehicle time was donated by the health ministry or its partners, a cost estimate was included,
based on the duration of mapping and the average daily cost of vehicle hire in previous pro-
grammes (mean cost of daily vehicle hire: Malawi MKW90,000, Nigeria NGN15,000, United
Republic of Tanzania TZS150,000, Zambia ZMW341, Zimbabwe USD$180).
Finally, administrative costs charged by implementing partners were excluded from the
expenditure analysis on the basis that rates were agreed contractually and did not necessarily
reflect the actual overhead costs of implementing partners.
Data collection
All data were collected retrospectively between June 2015 and March 2016. Financial data
were obtained via country-specific budgets and expenditure claim forms submitted by in-
country implementing partners. Financial data were extracted from the GTMP financial
reporting system (CLAIMS) or collected via Excel spreadsheets. Other data, such as the list of
EUs, districts, and clusters mapped for each subproject, were provided by the GTMP data
managers who cleaned and analysed all field data. Specific information on in-country surveys
was also collected through narrative reports and email or phone queries to implementing
partners.
Data analysis
GTMP expenditure was allocated to two categories of activity (in-country survey and global
support expenditures) and further divided into five sub-categories as indicated in Table 1.
Global support expenditure was broken down into three activities: grant management, epi-
demiological support, and data stewardship and processing.
In-country survey expenditure was allocated to either training or survey implementation
sub-categories. Since it was not possible to link training expenditure to specific subprojects
(because training activities often involved groups of trainees destined to work in different sub-
projects), this expenditure has been allocated to each subproject in proportion to the number
of EUs surveyed. Details of items included or excluded for each activity and sub-activity are
provided in Table 2.
Data were collected and analyzed in Excel and Stata 12.0 (Stata Corp, TX, USA). Descriptive
statistics were calculated including means, medians and interquartile ranges (IQRs) since in-
country survey expenditure by country or subproject did not follow a normal distribution. The
IQR includes all values between the 25th and 75th percentile, while outliers are defined as any
values above the 95th percentile. It was not possible to allocate survey expenditure to specific
EUs, districts or clusters, given that financial data were aggregated and reported by partners at
subproject level. The mean unit cost of mapping was hence obtained by dividing the total
expenditure by the number of districts, EUs and clusters surveyed in each subproject.
Currency and purchasing power parity
In-country survey and global operational expenditure were converted in US Dollars (USD)
using the mean annual market exchange rates over the mapping period [11]. All USD expenses
Table 1. Composition of GTMP expenditure.
Overall expenditure
In-country survey expenditure Global support expenditure
Survey implementation Training Grant management Epidemiological support Data stewardship
and processing
https://doi.org/10.1371/journal.pntd.0006023.t001
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were then inflated by applying the United States Consumer Price Index, using 2015 as the base
year [12]. In order to facilitate cross-country comparisons, the mean survey expenditure per
cluster was also converted to International Dollars. An international dollar is a hypothetical
currency adjusted by purchasing power parity conversion factors to compensate for price level
differences between countries [13]. Therefore, each country’s mean expenditure has been
divided by the latest Purchasing Power Parity conversion factors available for each country
(PPP, private consumption) [14]. Figures in International Dollars (PPP) are provided in the
results section.
Ethics statement
Ethics clearance for the costing study was granted by the London School of Hygiene & Tropi-
cal Medicine ethics committee (reference 11195). The research used routine financial data
from the project and did not require additional primary data collection. The underlying epide-
miological data were collected during the GTMP and ethics clearance was obtained from the
London School of Hygiene & Tropical Medicine (references 6319 and 8355) and from relevant
ethical review boards identified by the ministry of health in each country [4]. Informed verbal
consent was sought for each survey participant or from the parent or legal guardian when the
participant was minor. Verbal consent was preferred over written consent considering that
surveys were generally conducted in rural areas with high illiteracy rates. Verbal consent was
requested and recorded using the LINKS application (purpose-built application on Android
smartphones used for data collection).
Table 2. GTMP in-country survey expenditure composition by activity.
Activity Definition
Coordination &
planning
• Included: (i) Personnel and transport expenditure for survey coordination; (ii)
Expenditure related to community mobilisation and advocacy events, including
sensitisation meetings and mass media; (iii) Costs of contracting a specific
organization to co-ordinate partners in Ethiopia, Nigeria and Pakistan, due to the
scale of the work and the large number of implementing partners in these
countries*.
• Excluded: (i) In-country costs of dissemination of survey results (because this
activity was not standard and implemented in every country)
Fieldwork • Included: (i) Grader, recorder and village guide per diems, accommodation and
transportation expenditure for fieldwork; ii) Supplies (e.g., antibiotics to treat cases
of active trachoma identified); (iii) Other expenditures directly attributable to
fieldwork activities (e.g., examination loupes, mobile phone data plans to transmit
survey data, community based communication aids such as bags, t-shirts or caps,
postage).
• Excluded: Salaries of health ministry staff
Supervision • Included: (i) Supervisors’ per diems, accommodation, transportation and other
expenditure for supervising survey teams during fieldwork.
• Excluded: None
Training • Included: (i) Participants’ per diems, accommodation, and transportation
expenditure; (ii) Training venue rental; (iii) Supplies (if directly attributable to
training activities)
• Excluded: (i) International flights and fees for international trainers,
epidemiologist salaries—these costs are included in global support costs
*Amounting to US$ 44,889 for Ethiopia, US$ 46,941for Nigeria and US$ 45,956 for Pakistan), these
coordination fees were incurred in large countries where a specific organization was tasked with
coordinating the work of numerous partners.
https://doi.org/10.1371/journal.pntd.0006023.t002
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Results
Baseline trachoma mapping was completed for a total of 1,629 districts (993 EUs) in 32 coun-
tries [15–40]. Global support expenditures cover only districts which were mapped using stan-
dardised GTMP methodologies: 1,546 districts (905 EUs) in 29 countries. In-country survey
expenditures were calculated for 17 countries, including 1,164 districts (673 EUs) which met
our study inclusion criteria (Fig 2).
Global support expenditure
The total cost of the global GTMP support package was $5,129,348 (Table 3). This covered cen-
tralised support functions for rolling out the GTMP programme in 29 countries, as well as dis-
cussions with a further 20 countries in which mapping, ultimately, was not taken forward for
one of a variety of reasons, including excessive security risks or insufficient evidence to justify
conducting formal population-based prevalence surveys. Global support expenditure included
grant management (40%), epidemiological support (31%), and data stewardship and process-
ing (29%).
In-country survey expenditures
Overall, 89% of in-country survey expenditure was spent on survey implementation and 11%
on training. The mean training expenditure per mapping team was $2,357, ranging from $792
per team in Egypt to $8,513 in Pakistan. Survey implementation expenditures included field-
work (74%), coordination & planning (9%), and supervision (6%). When breaking down in-
country survey expenditure by inputs, personnel represented the highest share, accounting for
49% of total spend, followed by transportation (44%), supplies (4%), and other expenditure
(3%) (Table 4).
The median in-country survey cost was $15,839 per EU, ranging from $7,550 in Niger
State, Nigeria to $43,580 in Papua New Guinea. The mean cost per EU was $17,566 (IQR
$10,773–$19,915; SD = $9,470). As shown in Fig 3 on the “All regions” box plot, the mean unit
cost was higher than the median value because of four outliers: Papua New Guinea ($43,580),
Vanuatu ($42,795) and two regions in Ethiopia (Ethiopia Somali region $41,719; Gambella
region, $40,767). Fig 3 also shows that subprojects in the Middle East and North Africa had the
smallest variance in expenditures per EU, as demonstrated by their relatively low standard
deviation (US$ 4,309) compared to the Sub-Saharan African countries (US$ 9,277) and the
Pacific Islands and South Asia (US$ 12,777).
At cluster level, the median survey cost was $625, ranging from $290 in Zanzibar, United
Republic of Tanzania, to $1,687 in Papua New Guinea (mean of unit costs $692; IQR $452–
$847; SD = $350). Outlier values were Papua New Guinea ($1,687), Ethiopia Gambella region
($1,631) and Somali region ($1,558).
A summary of in-country survey expenditure by country and subproject is presented in
Table 5. More detailed information is also available in S1 Dataset.
Discussion
This study presents the costs of conducting trachoma prevalence surveys in suspected endemic
populations, with support from the GTMP. It is important to have setting-specific unit costs
for conducting trachoma prevalence surveys against which future surveys can be bench-
marked. Indeed, the evaluation of trachoma elimination efforts requires re-estimation of TF
and TT prevalence following implementation of the SAFE strategy. It is thus anticipated that
the need for surveys will increase in the near future as work is ramped up to meet the 2020
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trachoma elimination target. We believe that our work’s value is not limited to future efforts to
plan and budget for trachoma surveys. As one of the largest infectious disease mapping exer-
cises ever conducted, the GTMP offers important information for mapping other diseases too.
We find that the mean cost for trachoma prevalence surveys across our sample was $17,566
per EU. However, our analysis also shows that the level of expenditure for trachoma prevalence
Fig 2. Study inclusion flow diagram.
https://doi.org/10.1371/journal.pntd.0006023.g002
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surveys was substantially different between world regions, countries, and at sub-national level
(Table 5). These variations can be attributed to a number of parameters, including i) geo-
graphic location (topography, transport infrastructure, etc.); ii) demographic characteristics of
the population (population density, age groups, etc.); iii) seasonal effects (dry or wet season)
and iv) operational constraints (timeframe, security, logistics, unexpected events, NGOs’s
travel policies etc.). These parameters had an influence on the means of transportation, travel
distance, per diem rates and the duration of mapping, and consequently on transport and
personnel expenditure, which represented nearly 85% of the total cost of the surveys. When
comparing different parts of the world, these factors were key to accounting for unit cost
Table 3. Global GTMP support costs.
Category Description Total cost in
USD 2015 (%)
Average cost per district
in USD 2015 (n = 1,546)
Average cost per EU in
USD 2015 (n = 905)
Grant Management* Total 2,052,597 (40) 1,328 2,268
Audit, bank fees, communications, financial system
set up, flights and project management salaries
1,767,438
Monitoring and Evaluation 285,159
Epidemiological
support**
Total 1,601,903 (31) 1,036 1,770
Epidemiological Personnel Costs 1,359,015
International Flights 242,888
Data Stewardship and
Processing
Total 1,474,848 (29) 954 1,630
Data Management 1,022,583
Smartphone data collection system Development
and Maintenance
261,534
Smartphone purchase and shipping 190,731
Total Global GTMP
Support Cost
5,129,348 (100) 3,318 5,668
* Includes activities such as international coordination
** Transport and personal cost related to international technical experts who supported ministries of health designing their sampling methodology, plan
fieldwork activities; and implement survey.
https://doi.org/10.1371/journal.pntd.0006023.t003
Table 4. Percentage of in-country total survey expenditure by input and activity, in 2015 USD.
Inputs Activity
Survey implementation
Training (%) Fieldwork (%) Coordination & planning (%) Supervision (%) Total
Personnel 716,066 2.996,569 680,581 463,892 4,857,109 (49.5%)
(7.3%) (30.6%) (6.9%) (4.7%)
Transportation 292,633 3,768,103 70,224 143,636 4,274,596 (43.6%)
(3%) (38.4%) (0.7%) (1.5%)
Supplies 30,151 353,317 44 14 383,526 (3.9%)
(0.3%) (3.6%) (0%) (0%)
Other* 41,427 113,349 143,606 159 298,540 (3%)
(0.4%) (1.1%) (1.5%) (0%)
Total 1,080,276 7,231,338 894,455 607,701 9,813,770 (100%)
(11%) (73.7%) (9.1%) (6.2%)
*Communications expenses (sim cards, mobile data etc.), Insurance, Venue rental and Bank charges
https://doi.org/10.1371/journal.pntd.0006023.t004
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differences observed between the groups of subprojects in Sub-Saharan Africa, Middle-East
and North Africa, and Pacific Islands and South Asia.
In the Pacific Islands and South Asia, the survey unit cost and variance (mean = US$ 24,681
per EU, standard deviation = US$ 12,777) can be explained by low density of population, secu-
rity risks and relatively high price levels for commodities and services in some countries. In
Vanuatu, due to the island configuration and the low density of population, a high number of
clusters had to be surveyed across 17 islands in order to reach the required sample size. In
addition, in both Vanuatu and Papua New Guinea, survey teams had to travel by aircraft or
boat, which incurred high transport costs and increased the vulnerability of the work to
weather-related delay, such as tropical storms. For security reasons, training for the Pakistan
teams had to be conducted by international staff in Nigeria, increasing the cost of transporta-
tion for training participants. Finally, the high prices of commodities and services in island
nations such as Solomon Islands and Vanuatu further inflated survey costs there.
In Sub-Saharan Africa, unit cost variations between sub-projects can also be explained by
local conditions (mean = $16,734 per EU, SD = $9,277). The lowest survey costs were in Zanzi-
bar, United Republic of Tanzania (US$ 7,551 per EU) and Nigeria (US$ 8,577 per EU) because
of relatively high population densities and hence shorter mapping duration. On the other
hand, in some regions of Ethiopia (Gambella, Beneshangul Gumuz, Ethiopia Somali and
Afar), more resources were required to overcome implementation challenges caused by low
population densities, unpredictable environments and harsh climatic conditions, such as
extreme temperatures, volcanic activity and flooding. In Afar, for example, temperatures
exceeded 45˚C in the afternoon, and fieldwork was only possible for half of each day. In addi-
tion, remoteness and poor road infrastructure in some districts increased the time and
resources required to reach scattered clusters. As a result, the time required to map one cluster
increased substantially; resulting in high survey costs for the Gambella (US$ 40,767 per EU)
and Ethiopia Somali (US$ 41,719 per EU) regions compared to other subprojects.
Fig 3. In-country survey expenditure presented by world region (expenditure per EU, in 2015 USD).
Vertical boxes show the 25th and 75th percentile of the mean expenditure per EU. The median values are
represented by the horizontal bar in each box. Upper and lower bars show extreme values and dots indicate
outliers (outliers, defined with Tukey’s method, are values above 3rd quartile plus IQR times 1.5 and values
below 1st quartile plus IQR times 1.5 [41]).
https://doi.org/10.1371/journal.pntd.0006023.g003
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In contrast, with the notable exception of Darfur, Sudan, the contexts in which we worked
in the Middle East and North Africa group shared quite similar characteristics, in terms of
geography and population density. This underlies both the low mean unit cost ($15,252 per
EU) and low variance (SD = $4,309) observed there.
There is only one previously published study on the cost of trachoma mapping: by Chen
et al. [5]. Their analysis is based on data from eight national programmes in Sub-Saharan
Africa, covering a total of 165 districts and 1,203 clusters. Their quoted unit costs were lower
than ours, with a median cost per cluster of US$344 compared to US$625 for the GTMP, when
using the same base year (2015) [12]. However, caution is advised when comparing the overall
cost estimates between these two studies since the survey methodology, countries and districts
mapped, and the activities or expenditure included in the analysis, all diverged; in particular,
Chen et al. excluded the cost of international support in their district- and cluster-level analy-
ses. Despite these differences, both the previous work and ours found that transport and per
diems during field work were the main cost drivers for trachoma prevalence surveys. Chen
et al. also found large variations in survey unit costs; ranging from an average cost of US$
1,511 per district in Ethiopia to US$ 25,409 for Ayod in Southern Sudan. Moreover, similar
local factors affecting activity costs have also been observed on a published costing study con-
cerning lymphatic filariasis [42]. Hence, it is important for funders and program managers to
recognize the significant role that local factors play when planning and budgeting.
A specific and noteworthy example of this is that the level of supervision and epidemiologi-
cal support required can vary greatly from one setting to another. Supervision and coordina-
tion activities can increase the overall survey expenditure in situations where local capacity is
more limited; but are likely to reduce the risk of having to remap due to poor data quality. Sim-
ilarly, international experts are essential for training where local expertise is not available.
In the GTMP, the massive scale, the short timeline for implementation, as well as the drive
to produce objectively gold-standard data, required a significant level of investment in global
support systems including international coordination, centralised epidemiological support,
and single-source provision of data management services though a small, dedicated team. The
global support expenditures amounted to US$3,318 on average per district (US$ 5,668 per
EU). Although a global support expenditure of US$ 5,668 per EU is substantial when com-
pared to in-country survey expenditure, some of these costs would otherwise have been cov-
ered in-country in duplicative fashion, for example, through local costs for grant management,
data collection platform set-up, epidemiologist salaries, and creation of data processing sys-
tems. Undertaking the GTMP this way would have increased its overall cost.
Moreover, the GTMP was designed to be carried out quickly so that trachoma elimination
activities could start, where needed, in time to meet the global 2020 elimination target [4]. The
consequence is that 1,546 districts were surveyed over three years with full GTMP support,
compared to 1,115 districts mapped in 12 years prior to 2012. It is possible that survey expen-
diture would have been lower had survey activities been implemented only when conditions in
some areas were felt to be ideal: outside the rainy season, for example, or completely separated
from periods of risk for political or civil unrest. However, the higher cost of mapping to the
GTMP’s tight deadline is likely to be more than offset by accelerating the elimination of tra-
choma[43].
Our analysis is based on rigorous financial data obtained from the GTMP for 17 countries,
but had some limitations. First, the unit costs presented do not fully encapsulate the total eco-
nomic cost of conducting trachoma surveys, since they do not include donations and expendi-
ture that were not covered by the GTMP itself, particularly base salaries for health ministry
employees (outside of per diems covered by GTMP), apart from vehicles which costs have
been estimated and added to the appropriate survey cost (in instances when vehicles were
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made available by the health ministry or partners in Malawi, Nigeria, United Republic of Tan-
zania, Zambia and Zimbabwe). Second, budgeting and financial reporting in the GTMP was
done by subproject, and it was therefore not possible to allocate expenditure items to specific
district-level surveys. Unit costs presented in this paper are hence the average expenditures for
EUs, districts, and clusters within a subproject. Finally, in-country survey costs were estimated
based on subprojects that met our study inclusion criteria; 382 of 1,546 districts surveyed with
GTMP support were excluded.
Despite these limitations, this study provides data on the setting-specific costs of conduct-
ing trachoma prevalence surveys across 52 mapping subprojects and 17 countries, and adds
considerably to previous work [5]. The information we provide here can be used by endemic
countries and partners to help budget for future surveys. Data on the global distribution of
infectious diseases is increasingly available [44]; but significant knowledge gaps remain, even
for global priorities such as malaria, HIV and tuberculosis [45–47]. We hope that our work
can be used to guide studies that will start to close those gaps.
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